User profiles for Reed F. Beall
Reed F BeallAssistant Professor, University of Calgary Verified email at ucalgary.ca Cited by 906 |
[HTML][HTML] Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997
B Sahragardjoonegani, RF Beall… - … of pharmaceutical policy …, 2021 - Springer
Background Drug repurposing (ie, finding novel uses for existing drugs) is essential for
maximizing medicines’ therapeutic utility, but obtaining regulatory approval for new indications is …
maximizing medicines’ therapeutic utility, but obtaining regulatory approval for new indications is …
Evaluating the impact of the Orphan Drug Act's seven-year market exclusivity period
For thirty-five years the Orphan Drug Act of 1983 has provided incentives for pharmaceutical
manufacturers to develop drugs to treat rare diseases—conditions that affect fewer than …
manufacturers to develop drugs to treat rare diseases—conditions that affect fewer than …
Patents And Regulatory Exclusivities On Inhalers For Asthma And COPD, 1986–2020: Study examines patents and regulatory exclusivities on inhalers for asthma and …
Inhalers are the mainstay of treatment for asthma and chronic obstructive pulmonary disease
(COPD). These products face limited generic competition in the US and remain expensive. …
(COPD). These products face limited generic competition in the US and remain expensive. …
[HTML][HTML] Is patent “evergreening” restricting access to medicine/device combination products?
RF Beall, JW Nickerson, WA Kaplan, A Attaran - PLoS One, 2016 - journals.plos.org
Background Not all new drug products are truly new. Some are the result of marginal innovation
and incremental patenting of existing products, but in such a way that confers no major …
and incremental patenting of existing products, but in such a way that confers no major …
COVID-19 and the prevalence of drug shortages in Canada: a cross-sectional time-series analysis from April 2017 to April 2022
Background: In March 2020, the Government of Canada introduced measures to reduce
intensifying shortages of prescription drugs during the beginning of the COVID-19 pandemic. …
intensifying shortages of prescription drugs during the beginning of the COVID-19 pandemic. …
The characteristics of patents impacting availability of biosimilars
The large number of biologic drug patents in the United States has contributed to delays in
biosimilar availability.
biosimilar availability.
Pre-market development times for biologic versus small-molecule drugs
RF Beall, TJ Hwang, AS Kesselheim - Nature Biotechnology, 2019 - nature.com
3. Regalado, A. More than 26 million people have taken an at-home ancestry test. MIT
Technology Review https://www. technologyreview. com/s/612880/more-than-26-million-…
Technology Review https://www. technologyreview. com/s/612880/more-than-26-million-…
[HTML][HTML] Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019
Background Insulin is the primary treatment for type 1 and some type 2 diabetes but remains
costly in the United States, even though it was discovered more than a century ago. High …
costly in the United States, even though it was discovered more than a century ago. High …
Patents and regulatory exclusivities on GLP-1 receptor agonists
Importance Glucagon-like peptide 1 (GLP-1) receptor agonists were first approved for the
treatment of type 2 diabetes in 2005. Demand for these drugs has increased rapidly in recent …
treatment of type 2 diabetes in 2005. Demand for these drugs has increased rapidly in recent …
[HTML][HTML] A method for approximating future entry of generic drugs
Objectives To develop and test a method for approximating generic entry of top-selling drugs.
Methods The procedure involved 1) identifying products’ key patents as those with a patent …
Methods The procedure involved 1) identifying products’ key patents as those with a patent …